Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 5—May 2019
Research

Serologic Prevalence of Ebola Virus in Equatorial Africa

Imke Steffen1, Kai Lu, Lauren K. Yamamoto, Nicole A. Hoff, Prime Mulembakani, Emile O. Wemakoy, Jean-Jacques Muyembe-Tamfum, Nicaise Ndembi, Catherine A. Brennan, John Hackett, Susan L. Stramer, William M. Switzer, Sentob Saragosti, Guy O. Mbensa, Syria Laperche, Anne W. Rimoin, and Graham SimmonsComments to Author 
Author affiliations: Vitalant Research Institute, San Francisco, California, USA (I. Steffen, K. Lu, L.K. Yamamoto, G. Simmons); University of California, San Francisco (I. Steffen, K. Lu, G. Simmons); University of California, Los Angeles, California, USA (N.A. Hoff, A.W. Rimoin); University of Kinshasa, Kinshasa, Democratic Republic of the Congo (P. Mulembakani, E.O. Wemakoy); Institut National de Recherche Biomedicale, Kinshasa (J.-J. Muyembe-Tamfum); Institute of Human Virology, Abuja, Nigeria (N. Ndembi); Abbott Diagnostics, Abbott Park, Illinois, USA (C.A. Brennan, J. Hackett Jr.); American Red Cross Scientific Support Office, Gaithersburg, Maryland, USA (S.L. Stramer); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (W.M. Switzer); Institut National de la Santé et de la Recherche Médicale Unité 941, Paris, France (S. Saragosti); Centre National de Transfusion Sanguine, Kinshasa (G.O. Mbensa); Institut National de la Transfusion Sanguine, Paris (S. Laperche)

Main Article

Figure 5

Overlap of different assay results for Ebola virus serology across all samples in study of serologic prevalence of Ebola virus in equatorial Africa. A) Total sample set; B) sample sets from Kinshasha, Democratic Republic of the Congo; C) sample set from Kasaï Oriental Province, Democratic Republic of the Congo. LIPS, luciferase immunoprecipitation system; NA, not applicable (ELISA was performed only for samples with positive results in other assays); NP, nucleoprotein; VP40, matrix protein.

Figure 5. Overlap of different assay results for Ebola virus serology across all samples in study of serologic prevalence of Ebola virus in equatorial Africa. A) Total sample set; B) sample sets from Kinshasha, Democratic Republic of the Congo; C) sample set from Kasaï Oriental Province, Democratic Republic of the Congo. LIPS, luciferase immunoprecipitation system; NA, not applicable (ELISA was performed only for samples with positive results in other assays); NP, nucleoprotein; VP40, matrix protein.

Main Article

1Current affiliation: University of Veterinary Medicine, Hannover, Germany.

Page created: April 17, 2019
Page updated: April 17, 2019
Page reviewed: April 17, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external